Biotech gainers were led by CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection, improving reimbursement visibility for the modality. The group also saw strength in AtaiBeckley after it agreed to be acquired by Eli Lilly, signaling potential upside from strategic combination and commercialization pathways.
Biotech gainers were led by CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection, improving reimbursement visibility for the modality. The group also saw strength in AtaiBeckley after it agreed to be acquired by Eli Lilly, signaling potential upside from strategic combination and commercialization pathways.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
